This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated bullish coverage on Vita Coco, Toll Brothers, Civeo, Teva and Kura Oncology, with price targets of $70, $159, $42, $55 and $30.
Stocks · News reference
Caspian Therapeutics, Kura Oncology Plan To Devise Development Strategy For Caspian's KO-7246 Oral Menin Inhibitor Designed For Diabetes And Other Chronic Metabolic Diseases
Caspian Therapeutics, Inc. ("Caspian") and Kura Oncology, Inc. (Nasdaq: KURA, "Kura") plan to outline the development strategy for KO-7246, Caspian’s selective, oral menin inhibitor designed for diabetes
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30
Caspian Therapeutics And Kura Oncology Released Comprehensive Preclinical Data Supporting KO-7246 For Diabetes
Caspian Therapeutics, Inc. ("Caspian") and Kura Oncology, Inc. (NASDAQ:KURA, "Kura"))) today announced comprehensive preclinical data supporting KO-7246 as a potential best-in-class menin inhibitor for